Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

25 May 2018

Abstract excerpt

Abstract We used whole-genome and transcriptome sequencing to identify clinically actionable genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC). Molecular characterization of 17 patients with PDAC enrolled in a precision oncology program revealed gene fusions amenable to pharmacologic inhibition by small-molecule tyrosine kinase inhibitors in all patients with KRAS wild-type (KRASWT)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Chronic Lymphocytic Leukemia Research
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29802158
DOI: 10.1158/2159-8290.cd-18-0036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NRG1 Fusions in KRAS Wild-Type Pancreatic CancerPMID 29802158Read ↗

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic CancerSemantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.Semantic proximity Read ↗

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genesSemantic proximity Read ↗

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic CancerSemantic proximity Read ↗

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

Moving the Needle on Precision Medicine in Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.